Among these genes, 33 (16%; referring to 200 gene‐cancer pairs) were under clinical trial evaluation; 23 of 33 (70%) were anticancer drug targets; 23 of 33 (70%) are still active or complete in clinical trials, with drugs targeting four genes, LIPA, MAP2K1, PSMB5 and NDUFB3 already having been launched for treatment of cancers or diabetes. This evidence concerns the gene MAP2K1 and diabetes mellitus.